{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:40:48Z","timestamp":1777578048062,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005407","name":"Food and Health Bureau","doi-asserted-by":"publisher","award":["COVID19F01"],"award-info":[{"award-number":["COVID19F01"]}],"id":[{"id":"10.13039\/501100005407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in patients with cancer contributing to vaccine hesitancy in this population. We aimed to evaluate the association between BNT162b2 and CoronaVac vaccines and the risk of AESI in adults with active cancer or a history of cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>We conducted a territory-wide cohort study using electronic health records managed by the Hong Kong Hospital Authority and vaccination records provided by the Department of Health. Patients with a cancer diagnosis between January 1, 2018, and September 30, 2021, were included and stratified into two cohorts: active cancer and history of cancer. Within each cohort, patients who received two doses of BNT162b2 or CoronaVac were 1:1 matched to unvaccinated patients using the propensity score. Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for AESI 28 days after the second vaccine dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 74,878 patients with cancer were included (vaccinated: 25,789 [34%]; unvaccinated: 49,089 [66%]). Among patients with active cancer, the incidence of AESI was 0.31 and 1.02 per 10,000 person-days with BNT162b2 versus unvaccinated patients and 0.13 and 0.88 per 10,000 person-days with CoronaVac versus unvaccinated patients. Among patients with history of cancer, the incidence was 0.55 and 0.89 per 10,000 person-days with BNT162b2 versus unvaccinated patients and 0.42 and 0.93 per 10,000 person-days with CoronaVac versus unvaccinated patients. Neither vaccine was associated with a higher risk of AESI for patients with active cancer (BNT162b2: HR 0.30, 95% CI 0.08\u20131.09; CoronaVac: 0.14, 95% CI 0.02\u20131.18) or patients with history of cancer (BNT162b2: 0.62, 95% CI 0.30\u20131.28; CoronaVac: 0.45, 95% CI 0.21\u20131.00).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this territory-wide cohort study of patients with cancer, the incidence of AESI following vaccination with two doses of either BNT162b2 or CoronaVac vaccines was low. The findings of this study can reassure clinicians and patients with cancer about the overall safety of BNT162b2 and CoronaVac in patients with cancer, which could increase the COVID-19 vaccination rate in this vulnerable group of patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-022-01265-9","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T09:07:04Z","timestamp":1652951224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7617-6323","authenticated-orcid":false,"given":"Wei","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1084-1829","authenticated-orcid":false,"given":"Jessica J. P.","family":"Shami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-3032","authenticated-orcid":false,"given":"Vincent K. C.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9316-4666","authenticated-orcid":false,"given":"Xuxiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-198X","authenticated-orcid":false,"given":"Joseph E.","family":"Blais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-7808","authenticated-orcid":false,"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6283-978X","authenticated-orcid":false,"given":"Victor H. F.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8726","authenticated-orcid":false,"given":"Celine S. L.","family":"Chui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9121-1959","authenticated-orcid":false,"given":"Francisco T. T.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-1147","authenticated-orcid":false,"given":"Eric Y. F.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-6071","authenticated-orcid":false,"given":"Carlos K. H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"issue":"6","key":"1265_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/COC.0000000000000712","volume":"43","author":"OM Al-Quteimat","year":"2020","unstructured":"Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. 2020;43(6):452\u20135.","journal-title":"Am J Clin Oncol"},{"key":"#cr-split#-1265_CR2.1","unstructured":"Centre for Health Protection, Hong Kong Department of Health. Interim Guidance Notes On Common Medical Diseases and COVID-19 Vaccination In Primary Care Settings [Internet]. Hong Kong 2021 [updated 2021 November 24"},{"key":"#cr-split#-1265_CR2.2","unstructured":"cited 2022 January 25]. https:\/\/www.covidvaccine.gov.hk\/pdf\/Guidance_Notes.pdf."},{"key":"#cr-split#-1265_CR3.1","unstructured":"Centers for Disease Control and Prevention. COVID-19 Vaccines for Moderately or Severely Immunocompromised People [Internet]. 2022 [updated 2022 January 7"},{"key":"#cr-split#-1265_CR3.2","unstructured":"cited 2022 January 25]. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html."},{"key":"1265_CR4","doi-asserted-by":"publisher","first-page":"100441","DOI":"10.1016\/j.lanwpc.2022.100441","volume":"23","author":"J Xiao","year":"2022","unstructured":"Xiao J, Cheung JK, Wu P, Ni MY, Cowling BJ, Liao Q. Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: serial cross-sectional surveys. Lancet Reg Health West Pac. 2022;23:100441.","journal-title":"Lancet Reg Health West Pac"},{"issue":"15","key":"1265_CR5","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.3390\/cancers13153883","volume":"13","author":"JY Chun","year":"2021","unstructured":"Chun JY, Kim SI, Park EY, Park SY, Koh SJ, Cha Y, et al. Cancer patients\u2019 willingness to take COVID-19 vaccination: a nationwide multicenter survey in Korea. Cancers (Basel). 2021;13(15):3883.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1265_CR6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/vaccines9070792","volume":"9","author":"WL Chan","year":"2021","unstructured":"Chan WL, Ho YT, Wong CK, Choi HC, Lam KO, Yuen KK, et al. Acceptance of COVID-19 vaccination in cancer patients in Hong Kong: approaches to improve the vaccination rate. Vaccines (Basel). 2021;9(7):792.","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"1265_CR7","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.31557\/APJCP.2021.22.11.3499","volume":"22","author":"H Khiari","year":"2021","unstructured":"Khiari H, Cherif I, M\u2019Ghirbi F, Mezlini A, Hsairi M. COVID-19 vaccination acceptance and its associated factors among cancer patients in Tunisia. Asian Pac J Cancer Prev. 2021;22(11):3499\u2013506.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"14","key":"1265_CR8","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.3390\/cancers13143573","volume":"13","author":"ACP So","year":"2021","unstructured":"So ACP, McGrath H, Ting J, Srikandarajah K, Germanou S, Moss C, et al. COVID-19 vaccine safety in cancer patients: a single centre experience. Cancers (Basel). 2021;13(14):3573.","journal-title":"Cancers (Basel)"},{"issue":"24","key":"1265_CR9","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-21-2439","volume":"27","author":"V Di Noia","year":"2021","unstructured":"Di Noia V, Pimpinelli F, Renna D, Barberi V, Maccallini MT, Gariazzo L, et al. Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution. Clin Cancer Res. 2021;27(24):6815\u201323.","journal-title":"Clin Cancer Res"},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jnci\/djab174","volume":"114","author":"H Ligumsky","year":"2021","unstructured":"Ligumsky H, Safadi E, Etan T, Vaknin N, Waller M, Croll A, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients. J Natl Cancer Inst. 2021;114:203\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"1265_CR11","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.2217\/fon-2021-0597","volume":"17","author":"C Karacin","year":"2021","unstructured":"Karacin C, Eren T, Zeynelgil E, Imamoglu GI, Altinbas M, Karadag I, et al. Immunogenicity and safety of the coronavac vaccine in patients with cancer receiving active systemic therapy. Future Oncol. 2021;17(33):4447\u201356.","journal-title":"Future Oncol"},{"issue":"6","key":"1265_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Barrio DMD, I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765\u201378.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1265_CR13","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.3390\/cancers13225829","volume":"13","author":"P Trillo Aliaga","year":"2021","unstructured":"Trillo Aliaga P, Trapani D, Sandoval JL, Crimini E, Antonarelli G, Vivanet G, et al. Safety of COVID-19 mRNA vaccines in patients with cancer enrolled in early-phase clinical trials. Cancers (Basel). 2021;13(22):5829.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1265_CR14","doi-asserted-by":"publisher","first-page":"e28561","DOI":"10.1097\/MD.0000000000028561","volume":"101","author":"W Kian","year":"2022","unstructured":"Kian W, Zemel M, Kestenbaum EH, Rouvinov K, Alguayn W, Levitas D, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: a retrospective single-center study. Medicine (Baltimore). 2022;101(2):e28561.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1265_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/1759-7714.14281","volume":"13","author":"T Tamura","year":"2022","unstructured":"Tamura T, Ninomiya K, Kubo T, Kuyama S, Tachibana S, Inoue K, et al. Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: a multicenter, prospective, observational study. Thorac Cancer. 2022;13(3):453\u20139.","journal-title":"Thorac Cancer"},{"issue":"4","key":"1265_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.annonc.2020.12.019","volume":"32","author":"C Corti","year":"2021","unstructured":"Corti C, Curigliano G. Commentary: SARS-CoV-2 vaccines and cancer patients. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(4):569\u201371.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"27","key":"1265_CR17","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"key":"1265_CR18","doi-asserted-by":"crossref","unstructured":"Palacios R, Batista AP, Albuquerque CSN, Pati\u00f1o EG, Santos JdP, Conde MTRP, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV Study. SSRN; 2021.","DOI":"10.2139\/ssrn.3822780"},{"issue":"1","key":"1265_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","volume":"22","author":"EYF Wan","year":"2022","unstructured":"Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, et al. Bell\u2019s Palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22(1):64\u201372.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1265_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41467-022-28068-3","volume":"13","author":"FTT Lai","year":"2022","unstructured":"Lai FTT, Huang L, Chui CSL, Wan EYF, Li X, Wong CKH, et al. Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong. Nat Commun. 2022;13(1):411.","journal-title":"Nat Commun"},{"issue":"3","key":"1265_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.7326\/M21-3700","volume":"175","author":"FTT Lai","year":"2022","unstructured":"Lai FTT, Li X, Peng K, Huang L, Ip P, Tong X, et al. Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine\u202f: a case-control study. Ann Intern Med. 2022;175(3):362\u201370.","journal-title":"Ann Intern Med"},{"key":"1265_CR22","doi-asserted-by":"publisher","first-page":"100393","DOI":"10.1016\/j.lanwpc.2022.100393","volume":"21","author":"EYF Wan","year":"2022","unstructured":"Wan EYF, Chui CSL, Wang Y, Ng VWS, Yan VKC, Lai FTT, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. Lancet Reg Health West Pac. 2022;21:100393.","journal-title":"Lancet Reg Health West Pac"},{"key":"1265_CR23","doi-asserted-by":"crossref","unstructured":"Lai FTT, Huang L, Peng K, Li X, Chui CSL, Wan EYF, et al. Post-Covid-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection. J Intern Med. 2022.","DOI":"10.1111\/joim.13453"},{"issue":"8","key":"1265_CR24","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","volume":"7","author":"A Massarweh","year":"2021","unstructured":"Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133\u201340.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1265_CR25","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/jth.14219","volume":"16","author":"AA Khorana","year":"2018","unstructured":"Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O\u2019Connell C, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891\u20134.","journal-title":"J Thromb Haemost"},{"key":"1265_CR26","unstructured":"World Health Organization. COVID-19 Vaccines: Safety Surveillance Manual [Internet]. [updated 2020; cited 2022 January 25]. https:\/\/apps.who.int\/iris\/handle\/10665\/338400. License: CC BY-NC-SA 3.0 IGO."},{"key":"1265_CR27","doi-asserted-by":"publisher","first-page":"n1435","DOI":"10.1136\/bmj.n1435","volume":"373","author":"XT Li","year":"2021","unstructured":"Li XT, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373:n1435.","journal-title":"BMJ"},{"issue":"4","key":"1265_CR28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/annrheumdis-2021-221571","volume":"81","author":"X Li","year":"2022","unstructured":"Li X, Tong X, Yeung WWY, Kuan P, Yum SHH, Chui CSL, et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2022;81(4):564\u20138.","journal-title":"Ann Rheum Dis"},{"key":"#cr-split#-1265_CR29.1","unstructured":"Food and Health Bureau The Government of the Hong Kong Special Administrative Region. Report on Evaluation of Safety, Efficacy and Quality of Comirnaty COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection [Internet]. [updated 2022 January 12"},{"key":"#cr-split#-1265_CR29.2","unstructured":"cited 2022 April 7]. https:\/\/www.fhb.gov.hk\/download\/our_work\/health\/201200\/e_evaluation_report.pdf."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01265-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01265-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01265-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T09:20:57Z","timestamp":1652952057000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01265-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01265-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the University of Hong Kong\/Hospital Authority Hong Kong West Cluster (Reference Number: UW21-149) and the Department of Health Ethics Committee (LM21\/2021). Informed patient consent was not required as the data used in this study were anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"XL has received internal funding from the University of Hong Kong; consultancy fees from Merck Sharp & Dohme; research and educational grants from Janssen and Pfizer; research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region; all of which are outside this work. CSLC has received personal fees from Prime Vigilance; Hong Kong Innovation and Technology Commission from Pfizer, IQVIA, and Amgen; research grants from the Food and Health Bureau of the Hong Kong Government of the Hong Kong Special Administrative Region; all of which are outside this work. FTTL has received the RGC Postdoctoral Fellowship from the Hong Kong Research Grants Council; research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region; both of which are outside this work. EYFW has received research grants from the Hong Kong Research Grants Council; research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region; both of which are outside this work. CKHW reports receipt of research funding from the EuroQoL Group Research Foundation, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund; all of which are outside this work. ICKW has received research supports from Amgen, Bayer, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer, the Hong Kong Research Grants Council, the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region; the National Health and Medical Research Council in Australia; National Institute for Health Research in England, European Commission, speaker fees from Janssen and Medice in the previous three years; and is an independent non-executive director of Jacobson Medical in Hong Kong; all of which are outside this work. EWC has received research funds and grants from Research Grants Council (RGC, Hong Kong), Research Fund Secretariat of the Food and Health Bureau, Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region, National Natural Science Fund of China, Amgen, Bayer, Bristol-Myers Squibb, Janssen, Pfizer, Takeda, Wellcome Trust; and reports honorarium from Hospital Authority; all of which are outside this work. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}